FDA Issues Complete Response Letter for Abeona’s Pz-cel for Epidermolysis Bullosa
The CRL indicates that the timing proposed for data submission would not allow enough time for the FDA to complete its review by the May 25 PDUFA date.
The CRL indicates that the timing proposed for data submission would not allow enough time for the FDA to complete its review by the May 25 PDUFA date.
This case report describes an adult male patient with a severe acneiform eruption on his chest and back.
Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. This 60-minute live and virtual symposium will include expert faculty engaged in a fast-paced,…
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the newer treatments in AD, highlighting the positive impact these agents have had…
A new review highlighted JAK inhibitors’ role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.
This recap of skin cancer innovations accompanies the cover story of our May publication.
A 69-year-old man with a history notable for nonmelanoma skin cancer and being a nonsmoker sought dermatologic evaluation for a persistent, nonhealing lesion on his…
A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.
by Jacob Beer, MD; Sarah Hermak, MS; and Omar Noor, MD, FAAD Dr. Beer and Ms. Hermak are with the Dr. Phillip Frost Department of…
HMP Global launched a MATE Training Site to help prescribers earn their newly required CME credits. The M edication A ccess and T raining E…
This cohort study examines the association between methotrexate use and interstitial lung disease in patients with dermatomyositis.